End of the way for narlaprevir (SCH 900518), MK-7009 is the chosen one:
Merck had to choose among similar drugs in two research areas: hepatitis C and cancer. In December, Merck said its hepatitis C drug, MK-7009, also known as vaniprevir, would take priority over a similar drug from Schering.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.